Plus Therapeutics Subsidiary CNSide Diagnostics Achieves CLIA Accreditation for CNS Cancer Testing Lab
CNSide Diagnostics has received CMS accreditation for its clinical laboratory, enabling broader patient access and insurance coverage for its cerebrospinal fluid assay platform used in central nervous system cancer detection.
CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics, has received certificate of accreditation from CMS for its Houston-based clinical laboratory, marking a significant regulatory milestone for the company's central nervous system cancer diagnostic platform. The accreditation confirms compliance with Clinical Laboratory Improvement Amendments (CLIA) regulations enforced by the Centers for Medicare & Medicaid Services, which establish federal standards for laboratories conducting human specimen testing.
Russ Bradley, CNSide Diagnostics President and General Manager, stated that this achievement represents a key milestone in bringing the CNSide cerebrospinal fluid assay platform to the broadest possible set of patients with or at risk for CNS cancers while demonstrating commitment to the highest quality standards. The certification ensures laboratories meet all requirements for proficiency testing, personnel qualifications, and quality control measures.
The accreditation enables several critical commercial objectives, including obtaining state licensure in 48 of 50 states, securing broad-based commercial insurance coverage by making the laboratory eligible for reimbursement from private payors, and accessing government payor coverage through enrollment in Medicare and Medicaid programs. Additionally, the accreditation serves as a necessary step for pursuing and registering unique reimbursement billing codes that facilitate broader adoption of the diagnostic testing services.
CNSide Diagnostics develops and commercializes proprietary laboratory-developed tests, including the CNSide platform, which identifies tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The technology enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in cerebrospinal fluid, providing critical information for managing patients with leptomeningeal metastases. Plus Therapeutics, the parent company, focuses on developing targeted radiotherapeutics for difficult-to-treat central nervous system cancers, with lead programs in leptomeningeal metastases and recurrent glioblastoma. For more information about the company's developments, visit https://www.plustherapeutics.com.